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Abstract
Background:  Henoch Schönlein Purpura (HSP) is the most common systemic vasculitis of
childhood. There is considerable controversy over whether children with HSP should be treated
with corticosteroids. The goal of this study was to investigate whether early corticosteroid
administration could reduce the rate of renal or gastrointestinal complications in children with HSP.
Methods: Forty children with HSP, seen in the emergency room of a tertiary-care, paediatric
centre, entered a randomized, double-blind, placebo controlled study. The treatment group (n =
21) received oral prednisone, 2 mg/kg/day for one week, with weaning over a second week, while
the placebo group (n = 19) received an identical appearing placebo. Co-primary outcomes were
the rate of renal involvement at one year and the rate of acute gastrointestinal complications. Co-
primary outcomes were analysed using Fisher's Exact test.
Results: At one year, there was no difference in the rate of renal involvement (3/21 prednisone
group vs. 2/19 placebo group, P = 1.0). There was also no statistically significant difference in the
rate of acute gastrointestinal complications (2/21 prednisone group vs. 3/19 placebo group, P = 0.7).
Two children in the placebo group did experience intussusceptions compared with none in the
prednisone group (P = 0.2).
Conclusions: Early prednisone therapy in HSP does not appear to reduce the risk of renal
involvement at one year, or the risk of acute gastrointestinal complications. There may be a
reduced risk of intussusception. The routine, early use of prednisone in uncomplicated HSP cannot
be recommended at this time.
Background
Henoch Schönlein purpura (HSP) is a systemic, IgA-medi-
ated, small vessel vasculitis which is common in children
[1]. It is characterized by palpable purpuric rash, arthral-
gias or arthritis with periarticular swelling, bowel involve-
ment and renal involvement. There have also been reports
on the involvement of other organs, including lungs [2],
brain [3], and testes [4].
In the majority of children, HSP is a self-limited illness
with no significant sequelae. However, adverse outcomes
are possible. Acutely, bowel involvement may be
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associated with gastrointestinal haemorrhage in 5%,
intussusception in 2% or perforation in less than 1% [5].
Chronically, renal involvement may be associated with
some degree of renal insufficiency in 5%, and rarely,
chronic renal failure in up to 1.5% [6]. Persistent evidence
of renal involvement (microscopic haematuria, proteinu-
ria or hypertension) is reported to be present at greater
than one year of follow up in 35–53% of children,
although this figure is likely to be an overestimate given
the data are from referral-based, tertiary-care populations
[6-8].
Predicting which children are at risk of complications in
HSP has been difficult. Hypertension, proteinuria >1 g/l,
and elevations in serum urea and creatinine have been
shown to be risk factors for chronic renal disease [6,8-10].
One group has also identified age greater than seven years,
persistence of purpuric rash and low Factor XIII activity as
risk factors [11]. In a study of unselected children from
Northwest Spain with at least one year follow up, haema-
turia at the onset of the disease or renal manifestations
within the first three months after the onset of the symp-
toms of the disease were significantly more common in
the group of HSP patients with renal sequelae [12]. Also
in this study, the presence of nephritic syndrome during
the course of the disease was generally associated with
permanent renal involvement. Unfortunately, some of
these may be late findings, and may not be helpful in the
acute management of HSP. More importantly, once estab-
lished, chronic renal disease due to HSP may not be ame-
nable to therapy. Risk factors for gastrointestinal
complications have not been evaluated.
It has been proposed that the early use of corticosteroids
in children with HSP could prevent chronic renal disease.
There have been eight publications addressing this issue
[8,11,13-18], including two by the same author with over-
lapping patients. Unfortunately, these studies are fraught
with methodological flaws, and the only prospective
study failed to use appropriate randomization or a pla-
cebo [14]. Thus, the overall results are contradictory and
confusing, and the question of whether early treatment
with corticosteroids reduces the risk of subsequent renal
involvement in HSP remains unsettled. To date, no pro-
spective studies have investigated the effect of early treat-
ment with corticosteroids on gastrointestinal
complications.
This study is a randomized, placebo-controlled project
investigating whether early corticosteroid administration
could reduce the rate of renal or gastrointestinal compli-
cations in children with HSP. For the purposes of this
study, we have defined early administration of corticoster-
oid as within seven days of disease onset.
Methods
Patients
All children seen with a diagnosis of HSP in the emer-
gency room of the Children's Hospital of Eastern Ontario,
Ottawa, Canada between September 1, 1996 and January
31, 2000 were eligible for the study. HSP was defined as
palpable purpura and at least one of the following: arthri-
tis, renal involvement (defined as haematuria on urine
microscopy greater than or equal to 5 red blood cells per
high powered field or red cell casts, proteinuria of urinal-
ysis greater than or equal to 0.3 g/l, hypertension greater
than the 90th percentile for age and gender [19]); or gas-
trointestinal involvement (defined as abdominal pain,
gross or occult blood in stool, or a surgical complication,
such as intussusception or perforation). Eligible partici-
pants also had to be between 2 and 15 years of age and
within seven days of disease onset. Children were
excluded if there was another reason for purpura (e.g.
thrombocytopenia); if they had a known underlying sys-
temic vasculitis; if they had been treated with any corticos-
teroid in the previous month; if they were known to have
an underlying renal, gastrointestinal, or immunodefi-
ciency illness; if they currently had an active infection; or
if they were experiencing a life threatening complication
of HSP.
Objectives
The co-primary objectives of this study were to determine
if the early use of prednisone therapy in children with HSP
could prevent the development of renal involvement at
one year, or the development of gastrointestinal compli-
cations in the acute period. The effects of the intervention
on duration of symptoms (abdominal pain, joint pain,
rash); need for admission; and risk of recurrence were also
investigated.
Intervention
This study was approved by the Research Ethics Board at
the Children's Hospital of Eastern Ontario, Canada and
informed consent was obtained from the parents/guardi-
ans of all participants. Before the start of the study, a com-
puter-generated sequence of random numbers were
placed in a series of plain, sealed envelopes with patient
numbers on them by the research pharmacist. These enve-
lopes were created and kept in the pharmacy, and only
opened at the time of subject randomization, again by the
research pharmacist. Individuals directly involved in the
study had no access to these envelopes. Subjects were ran-
domized in blocks of eight. Subjects had an equal chance
of being assigned to the treatment or placebo groups. The
intention was to enrol 20 children into both the treatment
and placebo groups. Those assigned to the treatment
group were given oral prednisone 2 mg/kg for seven days,
followed by a weaning dose of prednisone for the next
seven days (75% on days 8 and 9, 50% on days 10 and 11,BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/7
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25% on days 12, 13, and 14, then discontinue). A starting
dose of 2 mg/kg was chosen as it was the maximum dose
used in previous studies, and thought to be the most likely
to be effective. Those assigned to the placebo group
received an identical number of pills, and followed the
same schedule. In order to maintain blinding, both pred-
nisone and placebo tablets were placed in opaque, taste-
less gelatin capsules. The subjects and all individuals
involved in the enrolment and assessment of study partic-
ipants were blinded to the study group.
Subjects were evaluated at baseline, two weeks, one
month and one year, with urine collections at two, three
and six months. During the first 14 days of the study, a
structured diary was completed by the parent/guardian
that documented symptoms, compliance with medication
and side effects. The completed diary was collected on 39
subjects. At each visit, a structured history and physical
examination was performed. All urine specimens had dip-
stick testing of protein and blood, as well as microscopy.
Blood tests for complete blood count, erythrocyte sedi-
mentation rate, urea, creatinine, coagulation parameters,
immunoglobulins, complement components 3 and 4,
and albumin were done at baseline, and complete blood
count, urea and creatinine at the one year follow up.
Outcomes
Renal involvement at one year was defined as haematuria
on microscopy greater than 5 red blood cells per high
powered field, red cell casts, proteinuria greater than 0.3
g/l, hypertension greater than 90th percentile for age and
gender [19], or renal insufficiency indicated by an eleva-
tion in serum creatinine. Acute gastrointestinal complica-
tions were defined as gastrointestinal bleeding requiring
transfusion or fluid resuscitation, intussusception, perfo-
ration or need for operative intervention.
Analysis
The study population was described using nonparametric
descriptive statistics. Proportions were compared using χ2
or Fisher's Exact test as appropriate. Medians were com-
pared using the Mann-Whitney U-test. Because symptom
durations were censored at 14 days, they were compared
using the Kaplan-Meier method and Log-Rank test. The
ability of continuous variables to predict either renal
involvement at one year or gastrointestinal complications
was analysed using logistic regression. Analyses were per-
formed using DataDesk 6.1 for Windows (Data Descrip-
tion Inc., 1996, Ithaca NY, USA) and SAS (SAS 8.0 for
Windows, 1999, Cary NC, USA).
All subjects who actually began the study were included in
the analysis (intention to treat). For those subjects with
incomplete data, the last available assessment was used.
Results
Patients
The flow of patients in the study is summarized in Figure
1. One subject was randomized, but then declined to par-
ticipate further in the study, and was not included in the
analysis. Characteristics of both groups are shown in
Table 1. There were no statistically significant differences
between the groups (data not shown), although the pred-
nisone group did appear to have a somewhat higher pro-
portion of subjects with gastrointestinal involvement at
enrolment.
Renal involvement
At one year, three children in the prednisone group and
two children in the placebo group had evidence of renal
involvement, as defined in this study (P = 1.0 by Fisher's
Exact test). All of these children had persistent haematuria
and/or proteinuria. None had hypertension or renal
insufficiency.
A post-hoc power calculation was performed to assess the
risk of a Type II error. Assuming that the rate of renal
involvement at one year was similar to that seen in the
placebo population (2/19 = 10.5%), setting the risk of a
Type I error to α = 0.05, this study had a power of 91% to
detect a 50% reduction in the rate of renal involvement at
one year. An exploratory analysis was also performed to
see if differences existed between the two groups at other
time points. No differences in renal involvement were
seen between the two groups at six months (two in pred-
nisone group, one in placebo group, P = 1.0 by Fisher's
Exact test), three months (three in prednisone group, two
in placebo group, P  = 1.0 by Fisher's Exact test), two
months (four in prednisone group, three in placebo
group, P = 1.0 by Fisher's Exact test), one month (three in
both prednisone and placebo groups, P = 1.0 by Fisher's
Exact test) or two weeks (three in prednisone group, one
in placebo group, P = 0.6 by Fisher's Exact test). The pres-
ence of renal involvement at any time during follow up
was not different between the two groups (nine in pred-
nisone group, five in placebo group, P = 0.27 by χ2, df =
1).
Gastrointestinal complications
Acute gastrointestinal complications were seen in two
children in the prednisone group (both severe abdominal
pain requiring admission but no other intervention), and
three children in the placebo group (two intussuscep-
tions, both of which required operative intervention, and
one with severe abdominal pain required admission but
no other intervention) (P = 0.7 by Fisher's Exact test).
When considered separately, the risk of intussusception
was not statistically different between the two groups (P =
0.2 by Fisher's Exact test). No children required a blood
transfusion or experienced a bowel perforation.BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/7
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Duration of symptoms
Symptom durations, as recorded in the 14-day diary, are
summarised in Table 2. No statistically significant differ-
ences were seen between the two groups. There appeared
to be a trend for children in the prednisone group to have
shorter durations of rash and joint pain. The prednisone
group did tend to have a longer duration of abdominal
pain, although the two children with intussusception con-
tributed no data to this result.
Admission, recurrences and withdrawals
Two children were admitted in the prednisone group
(both severe abdominal pain), three in the placebo group
(the two with intussusception, the other with severe
abdominal pain) (P  = 0.7 by Fisher's Exact test).
Recurrences (primarily rash) were seen in two children in
the prednisone group and four children in the placebo
group (P = 0.4 by Fisher's Exact test).
Three children were withdrawn from the study by the
investigators, all in the placebo group (both children with
Flow diagram showing the progress of patients through the study Figure 1
Flow diagram showing the progress of patients through the study
Table 1: Subject demographics at study enrolment
Prednisone group (n = 21) Placebo group (n = 19)
Age, years – median (range) 5 (2–11) 6.1 (3–15)
Gender Female 81 2
Male 13 7
Ethnicity Caucasian 18 18
Other 31
Days since illness onset – median (range) 4 (1–7) 3 (1–7)
Symptoms at enrollment- number of subjects (%) Rash 21 (100) 19 (100)
Joint 17 (81) 18 (95)
Gastrointestinal 18 (86) 11 (58)
Renal 4 (19) 2 (11)
41 subjects enrolled in 
study
21 subjects in Prednisone Group 19 subjects in Placebo Group
1 subject declined to start therapy
21 completed protocol 16 completed protocol
3 withdrawals (2 intussusception, 1 severe 
rash)
No withdrawalsBMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/7
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intussusception and one child with severe and worsening
rash) (P = 0.1 by Fisher's Exact test). Both of the children
with intussusception required operative intervention, and
were treated with corticosteroids by their attending physi-
cians. The child with the increasing rash was not treated
with corticosteroids. All three of these children had une-
ventful and complete recoveries. No children experienced
significant adverse events secondary to prednisone
therapy.
Prediction of renal involvement or gastrointestinal 
complications
Age, time since diagnosis, Factor XIII level, and IgA level
were not significant predictors of either renal involvement
at one year or gastrointestinal complications, whether
using univariate analysis or bivariate analysis to account
for treatment group (Table 3).
Discussion
This project was a randomized, double-blind, placebo-
controlled study investigating the efficacy of early pred-
nisone therapy to prevent complications of HSP. We
found no evidence that early prednisone therapy reduced
the risk of renal involvement at one year. We also failed to
show a statistically significant difference in the risk of gas-
trointestinal complications, although there did appear to
be a trend towards reduced risk in the treatment group.
Somewhat surprisingly, we also did not see a statistically
significant difference in duration of symptoms, although
again there appeared to be a trend towards shorter dura-
tions of rash and joint pain in the treatment group.
Finally, unlike recent publications [11,15], we were
unable to identify any significant predictors of adverse
renal or gastrointestinal outcomes.
There remains considerable controversy regarding the use
of corticosteroids in uncomplicated HSP. This is under-
standable, considering the contradictory nature of the
literature. However, the lack of consistency between
studies is likely to be largely related to the inadequate
methods used to date.
Mollica et al have published the only prospective study of
the use of corticosteroids to prevent renal injury [14].
Unfortunately, interpretation of these results is hindered
by the lack of random group assignment (described as
being "alternatively assigned to one of two treatment
groups") and the lack of any description of blinding.
These deficiencies leave concerns regarding the possibility
of bias in this study and, despite the rather strikingly sig-
nificant results in favour of corticosteroid therapy, prevent
it from providing definitive evidence.
Table 2: Summary of symptom durations, based on 14-day diary data (all observations censored at 14 days).
Prednisone Placebo P-value by Log-rank test
Rash duration, days – median (range) (n = 39) 7 (0–14) 11 (0–14) 0.1
Joint pain duration, days – median (range) (n = 38) 3 (0–12) 6 (0–14) 0.1
Abdominal pain duration, days – median (range) (n = 39) 5.5 (0–14) 2 (0–14) 0.8
Table 3: Potential predictive variables for renal involvement at one year or gastrointestinal complications (using logistic regression)




β-coefficient P-value β-coefficient P-value
Univariate (predictor alone)
Age -0.06 0.4 0 1.0
Time since diagnosis 0 1.0 -0.02 0.6
Factor XIII level -0.2 0.6 -0.2 0.4
IgA level 0.09 0.5 0.01 0.9
Bivariate (predictor and treatment group)
Age -0.09 0.2 0.1 0.8
Time since diagnosis 0.01 0.8 -0.3 0.5
Factor XIII level -0.3 0.4 -0.1 0.6
IgA level 0.04 0.8 0.1 0.3BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/7
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The remaining studies concerning renal involvement are
retrospective, with corticosteroids given at the discretion
of the treating physician for a variety of indications. Some
of these studies suggested that corticosteroids were bene-
ficial in preventing renal involvement [11,13], while oth-
ers showed no benefit [8,15-18]. Unfortunately,
interpretation of these studies is hampered by their retro-
spective design. There is no reasonable expectation that
children who were treated were similar to those who were
not treated. In particular, it is likely that children with
more severe disease would be the most likely to be treated
with corticosteroids. This is likely to bias results against
showing a benefit for corticosteroid therapy and prevent
any of these studies providing useful information about
the role of corticosteroids in HSP.
The literature concerning gastrointestinal complications is
equally unhelpful. There have been no prospective trials.
Three retrospective studies have suggested that corticoster-
oids are beneficial in the treatment of abdominal pain
[17,20,21] and, although this does show consistency, it
cannot be considered definitive evidence.
In the current study, bias has been minimized by using a
randomized and double-blinded design. Variation in the
population has been minimized by ensuring that all par-
ticipants were early in their illness, with enrolment prior
to seven days. Both renal and gastrointestinal complica-
tions have been investigated. Thus, this study should pro-
vide high quality data concerning the use of
corticosteroids in HSP.
This study provides no evidence that corticosteroids
reduce the risk of renal involvement at one year. In fact,
the treatment group had a slightly higher (not statistically
significant) rate of renal involvement compared to the
placebo group. Although this was a relatively small study,
it had a power of over 90% to show a 50% reduction in
renal involvement at one year. Given that our definition
of renal involvement is acting as a surrogate marker for the
much rarer, and clinically relevant, outcome of chronic
renal insufficiency, it was felt that a 50% reduction would
be necessary to be considered significant.
Although this study did not show a statistically important
difference in the rate of gastrointestinal complications, it
is important to note that two children in the placebo
group did develop intussusceptions that required opera-
tive intervention, a complication that was not seen in the
treatment group. It is possible that the study was not large
enough to show a statistically significant difference, and
that the early use of corticosteroids in HSP may prevent
this important complication.
It is interesting that corticosteroid therapy did not seem to
reduce symptom duration. There is a trend towards
shorter durations of rash and joint pain in the treatment
group. A similar trend is not seen for abdominal pain.
Unfortunately, both children with intussusceptions were
withdrawn early from the study, and so contributed no
data about abdominal pain. It is possible that the loss of
this data may have compromised this part of the analysis.
Despite the methodological strengths of this study, there
are some limitations. The most important is the sample
size. However, we have shown that the study does have
reasonable power to demonstrate the size of benefit we
considered to be clinically relevant. The study might also
be criticized for the use of a surrogate outcome for the
development of chronic renal insufficiency. This is a rare
complication which may develop many years after the
acute illness, making a study with it as a primary outcome
impossible to perform. Finally, this study involved chil-
dren seen in the emergency room of a tertiary care paedi-
atric centre. It is possible that this may have skewed the
population towards more severe involvement.
Conclusions
In conclusion, this study did not show a difference in the
development of renal injury between children treated
with corticosteroids or placebo. These results do not sup-
port the use of corticosteroids in early HSP to prevent
renal injury. It is possible that corticosteroids prevent
some acute gastrointestinal complications. Given the




All authors participated in the initial design of the trial.
AH collected the data (with the assistance of the research
assistants), performed the analysis and drafted the initial
manuscript. MP supervised the conduct of the trial, and
facilitated data collection. All authors contributed to revi-
sions of the manuscript.
Acknowledgements
Our most sincere thanks to Terry Sutcliffe and Marni Baird who devoted 
so much time and effort to this project, and to Dr. Nina Birdi who was 
instrumental in the concept and design of this project and has been a men-
tor to Dr. Huber.
References
1. Saulsbury Frank T.: Henoch-Schonlein purpura.  Curr Opinion
Rheumatol 2001, 13:35-40.
2. Chaussain Michelle, de Boissieu Delphine, Kalifa Gabriel, Epelbaum
Serge, Niaudet Patrick, Badoual Jean, Gendrel Dominique: Impair-
ment of lung diffusing capacity in Schonlein-Henoch
Purpura. J Pediatr 1992, 121:12-16.
3. Chen Chein-Liang, Chiou Yee-Hsuan, Wu Chan-Yao, Lai Ping-Hong,
Chung Hsiao-Min: Cerebral vasculitis in Henoch-SchonleinPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medicine 2004, 2 http://www.biomedcentral.com/1741-7015/2/7
Page 7 of 7
(page number not for citation purposes)
purpura:a case report with sequential magnetic resonance
imaging changes and treated with plasmapheresis alone. Pedi-
atr Nephrol 2000, 15:276-278.
4. Ben-Sira Liat, Laor Tal: Severe scrotal pain in boys with Henoch
Schonlein purpura:incidence and sonography.  Pediatr Radiol
2000, 30:125-128.
5. Szer IS: Henoch-Schonlein purpura. Curr Opin Rheumatol 1994,
6:25-31.
6. Koskimies O, Mir S, Rapola J, Vilska J: Henoch Schonlein nephri-
tis:long-term prognosis of unselected patients. Arch Dis Child
1981, 56:482-484.
7. Goldstein AR, White HRW, Akuse R, Chantler C: Long-term fol-
low-up of childhood Henoch-Schonlein nephritis. Lancet 1992,
339:280-282.
8. Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR,
Bluett NH, Swetschin H, Cameron JS, Chantler C: Prognosis of
Henoch-Schonlein nephritis in children. BMJ 1977, 2:11-14.
9. Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP: Long-term
prognosis of Henoch-Schonlein nephritis in adults and
children. Nephrol Dial Transplant 1997, 12:2277-2283.
10. Niaudet P, Murcia I, Beaufils H, Broyer M, Habib R: Primary IgA
nephropathies in children: prognosis and treatment.  Adv
Nephrol Necker Hosp 1993, 22:121-140.
11. Kaku Yoshitsugu, Nohara Kaoru, Honda Sunao: Renal involvement
in Henoch-Schonlein purpura: A multivariate analysis of
prognostic factors. Kidney Int 1998, 53:1755-1759.
12. Calvino MC, Llorca J, Garcia-Porrua C, Fernandez-Iglesias JL, Rod-
riguez-Ledo P, Gonzalez-Gay MA: Henoch-Schonlein purpura in
children from northwestern Spain: a 20-year epidemiologic
and clinical study. Medicine (Baltimore) 2001, 80:279-290.
13. Buchanec J, Galanda V, Belakova S, Minarik M, Zibolen M: Incidence
of renal complications in Schonlein-Henoch purpura syn-
drome in dependence of an early administration of steroids.
Int Urol Nephrol 1988, 20:409-412.
14. Mollica F, Li Volti S, Garozzo R, Russo G: Effectiveness of early
prednisone therapy in preventing the development of neph-
ropathy in anaphylactoid purpura.  Eur J Pediatr 1992,
151:140-144.
15. Sano Hitomi, Izumida Michiko, Shimizu Hiroshi, Ogawa Yunisuke:
Risk factors for renal involvement and significant proteinuria
in Henoch-Schonlein purpura. Eur J Pediatr 2002, 161:196-201.
16. Saulsbury FT: Corticosteroid therapy does not prevent nephri-
tis in Henoch-Schonlein purpura. Pediatr Nephrol 1993, 7:69-71.
17. Saulsbury FT: Henoch-Schonlein purpura in Children. Report
of 100 patients and review of the literature. Medicine 1999,
78:395-409.
18. Temmel AFP, Emminger W, Schroth B, Zaunschirm HA, Gadner H:
Early prednisone therapy and nephropathy in anaphylactoid
purpura. Eur J Pediatr 1993, 152:782-783.
19. Task Force on Blood Pressure Control in Children. National
Heart, Lung and Blood Institute, Bethesda, Maryland.
Report of the Second Task Force of Blood Pressure Control
in Children. Pediatrics 1987, 79:1-25.
20. Rosenblum Norman D., Winter Harland S.: Steroid effects on the
course of abdominal pain in children with Henoch-Schonlein
purpura. Pediatrics 1987, 79:1018-1021.
21. Glasier CM, Siegel MJ, McAlister WH, Shackelford GD: Henoch-
Schonlein syndrome in children: gastrointestinal
manifestations. AJR Am J Roentgenol 1981, 136:1081-1085.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1741-7015/2/7/prepub